glp 1 for lupus Glucagon-like peptide-1 receptor agonist and nephritis in systemic lupus erythematosus with type 2 diabetes At Lupus LA’s #LatestOnLupus Conference

What makes this injection risky and how can you minimize the risks

This point-of-care test (POCT) kit is able to incorporate both enzyme activity and hemoglobin concentration measurement into the result, which is automatically calculated within the device

CagriSema development Combination therapy trials exploring optimal dosing ratios, different target populations, and head-to-head comparisons with existing therapies

Its dismal prognosis, with a 5-year survival rate below 10%, is largely attributable to late diagnosis, early metastatic dissemination, and profound resistance to conventional chemotherapy and radiotherapy [1]

GLP1 receptor agonists for the treatment of obesity: role as a promising approach

No evidence-based guidelines regarding the use of B 12 testing in people with suspected B 12 deficiency